aTyr Pharma Inc Expected to Post Q1 2017 Earnings of ($0.49) Per Share (LIFE)

aTyr Pharma Inc (NASDAQ:LIFE) – Analysts at William Blair issued their Q1 2017 earnings per share (EPS) estimates for shares of aTyr Pharma in a research report issued to clients and investors on Friday. William Blair analyst Y. Xu anticipates that the firm will earn ($0.49) per share for the quarter. William Blair also issued estimates for aTyr Pharma’s Q2 2017 earnings at ($0.50) EPS, Q3 2017 earnings at ($0.55) EPS, Q4 2017 earnings at ($0.63) EPS and FY2019 earnings at ($3.96) EPS.

Several other equities analysts have also weighed in on LIFE. JPMorgan Chase & Co. lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating and set a $2.85 price objective for the company. in a research report on Tuesday, December 13th. BMO Capital Markets restated a “market perform” rating and set a $4.00 price objective (down previously from $8.00) on shares of aTyr Pharma in a research report on Thursday, December 15th. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Citigroup Inc raised their price objective on shares of aTyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating, aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $3.71.

Your IP Address:

aTyr Pharma (NASDAQ:LIFE) opened at 3.70 on Monday. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $6.01. The company’s 50-day moving average is $3.46 and its 200 day moving average is $3.07. The firm’s market cap is $87.76 million.

In other aTyr Pharma news, Director Paul Schimmel acquired 25,000 shares of aTyr Pharma stock in a transaction dated Wednesday, December 21st. The stock was bought at an average price of $2.28 per share, for a total transaction of $57,000.00. Following the transaction, the director now owns 40,440 shares in the company, valued at approximately $92,203.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 28.90% of the company’s stock.

An institutional investor recently bought a new position in aTyr Pharma stock. EcoR1 Capital LLC bought a new stake in aTyr Pharma Inc (NASDAQ:LIFE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 976,986 shares of the company’s stock, valued at approximately $2,101,000. aTyr Pharma accounts for about 0.7% of EcoR1 Capital LLC’s portfolio, making the stock its 20th largest position. EcoR1 Capital LLC owned approximately 4.12% of aTyr Pharma as of its most recent filing with the SEC. Institutional investors own 44.84% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

5 Day Chart for NASDAQ:LIFE

Receive News & Ratings for aTyr Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.